Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AZ, NCC Ink Collaboration on Biomarkers for Lung Cancer Immunotherapy
December 20, 2016
- Hisamitsu Seeks Japan Approval for Allergic Rhinitis Tape Treatment
December 20, 2016
- Shionogi Hooks Up with Purdue on Naldemedine Commercialization in US
December 20, 2016
- Concerns Expressed Over High Cost of Regenerative Medicines; As with Opdivo, “Bound to Become Issue Again”
December 20, 2016
- Teva Takeda Recalls Dalteparin “Taiyo”
December 20, 2016
- Japan Osteoporosis Market to Expand 45.3% by 2024: Fuji Keizai
December 19, 2016
- Public Knowledge-Based Application Filed for Tamiflu’s New Pediatric Dosage
December 19, 2016
- Fujifilm Allies with Russia’s R-Pharm in Healthcare
December 19, 2016
- Otsuka Gets Exclusive Rights to Takara Bio’s Oncolytic Virus in Japan
December 16, 2016
- Continued Xtandi Treatment Fails to Extend PFS: US PIV Trial
December 16, 2016
- Belsomra Most Heavily Promoted Drug in HP Market October: Anterio
December 16, 2016
- Sysmex, Astellas, and Daiichi Sankyo Ink Memo to Create Method for Analyzing CTC
December 16, 2016
- Diovan Data Manipulation Case Closed, Ruling Due Out in March
December 16, 2016
- Shinjiro Sato Tapped as Next President of Terumo
December 16, 2016
- Aspen Japan, Kissei Sign Copromotion Pact on Imuran
December 16, 2016
- Fujifilm to Acquire Takeda’s Reagent Unit for 155 Billion Yen
December 16, 2016
- Nippon Kayaku Introduces “MSLs” to Strengthen Detailing for Oncology Generics, Biosimilars, and Products in Development
December 16, 2016
- Interview: GSK’s New Evaluation System for Sales Reps Helps Deliver Science-Based Message
December 15, 2016
- FunPep, Shionogi Enter Joint Research Agreement for Vaccine Adjuvants
December 15, 2016
- Daiichi Sankyo Aims to File Antibody Drug Conjugate DS-8201 in 2020 for HER2-Positive Breast Cancer, Stomach Cancer
December 15, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…